Arvinas, Inc.
NASDAQ:ARVNBiotechnology
-$0.10 today
- Market cap
- $443.01M
- Beta
- 1.75
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$3.46
Volume 1.09M
Average 0.89M
ARVN Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Arvinas, Inc.NASDAQ: ARVN
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $5.2M fell 55.6% year over year, behind the -42.1% change in trailing-twelve-month other income / expenses. Sequentially, it rose 15.6% from the prior quarter. Over 3 fiscal years it compounded at +178.1% a year.
Context
- Other income / expenses amounted to 13.1% of revenue in FY2025, down 6.6 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -55.6% toward the trailing-twelve-month pace of -42.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 34.4M USD
- Year-over-year change
- -33.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.4M | -33.7% |
| FY2024 | 2024-12-31 | 51.9M | +47.9% |
| FY2023 | 2023-12-31 | 35.1M | +2093.8% |
| FY2022 | 2022-12-31 | 1.6M | +161.5% |
| FY2021 | 2021-12-31 | (2.6M) | — |
Other Income / Expenses vs competitors
How ARVN compares with its peers on the latest reported figures
- ARVN's LTM Mar 2026 other income / expenses of $28.7M is the 2nd highest of the 6 companies compared; the peer median is $16.4M.
- Its year-over-year change of -42.1% is the 5th highest of 6, against a peer median of -20.1%.
- Other income / expenses amounts to 32.1% of revenue for ARVN, versus a peer median of 29.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $50.31M | +38.1% | +80.3% | 47.9% | |
| LTM Mar 2026 | $28.7M | -42.1% | +178.1% | 32.1% | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
| LTM Mar 2026 | $16.4M | +41.5% | +55.1% | 38.2% | |
| LTM Mar 2026 | $10.16M | -24.2% | — | 29.2% | |
| LTM Mar 2026 | $5.44M | -67.9% | -1.8% | 19.3% | |
| Peer median (excluding ARVN) | $16.4M | -20.1% | +67.7% | 29.2% | |
Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 53.6M | 131.4M | 78.5M | 263.4M | 262.6M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.2M |
| Gross Profit | 53.6M | 131.4M | 78.5M | 263.4M | 257.4M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 98.0% |
| Research & Development | 180.4M | 315M | 379.7M | 348.2M | 282.9M |
| Selling, General & Admin | 61.6M | 79.6M | 100.3M | 165.4M | 89.4M |
| Operating Expenses | 242M | 394.6M | 480M | 513.6M | 372.3M |
| Depreciation & Amortization | 6M | 8.2M | 6.7M | 6.6M | 5.2M |
| EBITDA | (184.9M) | (253.4M) | (359.7M) | (191.7M) | (75.3M) |
| EBITDA Margin | -345.0% | -192.8% | -458.2% | -72.8% | -28.7% |
| Operating Income | (188.4M) | (263.2M) | (401.5M) | (250.2M) | (114.9M) |
| Operating Margin | -351.5% | -200.3% | -511.5% | -95.0% | -43.8% |
| Interest Income | 1.8M | 12M | 38.8M | 54.8M | 22M |
| Interest Expense | 100K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.6M) | 1.6M | 35.1M | 51.9M | 34.4M |
| Income Before Tax | (191M) | (261.6M) | (366.4M) | (198.3M) | (80.5M) |
| Pre-Tax Margin | -356.3% | -199.1% | -466.8% | -75.3% | -30.7% |
| Income Tax Expense | 0 | 20.9M | 900K | 600K | 300K |
| Net Income | (191M) | (282.5M) | (367.3M) | (198.9M) | (80.8M) |
| Net Margin | -356.3% | -215.0% | -467.9% | -75.5% | -30.8% |
| EPS (Basic) | (3.82) | (5.31) | (6.62) | (2.77) | (1.28) |
| EPS (Diluted) | (3.82) | (5.31) | (6.62) | (2.77) | (1.28) |
| Weighted Avg Shares | 50M | 53.2M | 55.5M | 71.9M | 64.9M |
| Weighted Avg Shares (Diluted) | 50M | 53.2M | 55.5M | 71.9M | 64.9M |
Arvinas, Inc.
NASDAQ:ARVN
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.